Drugs / SCRI-CARB7H3(s)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04185038 | Dec 2019 → May 2027 expected | atypical teratoid rhabdoid tumor, childhood medulloblastoma, choroid plexus carcinoma, diffuse intrinsic pontine glioma +4 | Seattle Children's Hospital | Recruiting | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCRI-CARB7H3(s) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04185038 ↗ |
| Action | Deplete | “The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins.” PMID 35468680 ↗ Apr 2022 |
| Modality | Cell therapy | “Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt” NCT04185038 ↗ |
| Route | Other | “given via indwelling central nervous system (CNS) catheter” NCT04185038 ↗ |